Dyne Therapeutics Inc
DYN14.220USD
+0.980+7.40%
Fechamento 09/05, 16:00（ET）Cotações atrasadas em 15 min
1.63BValor de mercado
PerdaP/L TTM
Mais detalhes de Dyne Therapeutics Inc Empresa
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Informações da empresa
Código da empresaDYN
Nome da EmpresaDyne Therapeutics Inc
Data de listagemSep 17, 2020
CEOMr. John Cox
Número de funcionários191
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço1560 Trapelo Road
CidadeWALTHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02451
Telefone17817868230
Sitehttps://dyne-tx.com/
Código da empresaDYN
Data de listagemSep 17, 2020
CEOMr. John Cox
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
Outro
66.64%
Investidores
Investidores
Proporção
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
Outro
66.64%
Tipos de investidores
Investidores
Proporção
Investment Advisor
29.03%
Investment Advisor/Hedge Fund
24.17%
Venture Capital
21.19%
Hedge Fund
13.77%
Private Equity
3.36%
Research Firm
2.61%
Individual Investor
0.59%
Bank and Trust
0.28%
Pension Fund
0.19%
Outro
4.79%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
433
126.04M
90.68%
+6.43M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.72M
1.97%
+1.37M
+101.71%
Mar 31, 2025
TCG Crossover Management, LLC
2.65M
1.92%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Nome
Proporção
iShares Neuroscience and Healthcare ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Health Innovation Active ETF
0.11%
iShares Biotechnology ETF
0.09%
Optimize Strategy Index ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção2.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.8%
SPDR S&P Biotech ETF
Proporção0.27%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.18%
ProShares Ultra Nasdaq Biotechnology
Proporção0.12%
Invesco Nasdaq Biotechnology ETF
Proporção0.11%
iShares Health Innovation Active ETF
Proporção0.11%
iShares Biotechnology ETF
Proporção0.09%
Optimize Strategy Index ETF
Proporção0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
